Company profile
Agios Pharmaceuticals, Inc.
NASDAQ: AGIO · Healthcare · Biotechnology
#421 of 1,418 Healthcare companies by revenuetop-quartile growth
EA Score
70BFH 57DQ 90GM 68SS 75
v0.1 · 65/100 weight · provisional
↑ filing timeliness, balance-sheet leverage · ↓ operating margin, net margin
Methodology →Revenue TTM
$66.0M
Rev growth YoY (TTM)
+78.3%
Net income (FY)
-$412.8M
Employees
540
as of 2026-08-09
Market cap
$1.9B
as of 2026-08-09
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$54.0M$54.0M2025
Net income-$412.8M-$412.8M2025
Operating income-$472.1M-$472.1M2025
Total assets$1.3B$1.3B2025
Liabilities$104.1M$104.1M2025
Equity$1.2B$1.2B2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY22
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Product100%
By geography
UNITED STATES91%
Non-US9%
The read
What is Agios Pharmaceuticals, Inc.’s revenue?
Agios Pharmaceuticals, Inc. booked $54.0M in FY2025 revenue, growing 48% year over year — faster than most Healthcare companies we track, at a -764.0% net margin.
Peers · Healthcare
Nektar Therapeutics50DThe Joint Corp.75B+Integrated BioPharma, Inc.67BQ32 Bio Inc.72BInvivyd, Inc.41DRegional Health Properties, Inc.67BNeighbors
Middlesex →Key facts
CEOBrian Goff
SectorHealthcare
IndustryBiotechnology
HeadquartersCambridge, MA
ExchangeNASDAQ: AGIO
Employees540
IPO date2013-07-24
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.